Impressive Bleeding Profile With Factor XI Inhibitor in AF Impressive Bleeding Profile With Factor XI Inhibitor in AF

Further details from the phase 2b AZALEA trial of the factor XI inhibitor abelacimab show significant reductions in major and clinically relevant nonmajor bleeding vs rivaroxaban for patients with AF.Medscape Medical News

Source: Medscape Cardiology Headlines - November 13, 2023 Category: Cardiology Tags: Cardiology News Source Type: news